Michelle Gee is an experienced clinical development professional with a focus on Alzheimer's disease and brain health. Currently serving as Executive Director at Eisai since February 2011, Michelle leads clinical efforts for an investigational compound targeting Early Alzheimer's Disease and oversees a Phase 3 trial. Prior to this role, Michelle worked at GlaxoSmithKline from July 1997 to July 2010, where significant contributions were made as Director in the Development Sciences, Neurosciences Medicines Development Centre, managing various projects related to psychiatric conditions and diverse patient populations. Academic credentials include a PhD in Physiology from UCL and a BSc Hons in Physiology from the University of Bristol.
This person is not in the org chart
This person is not in any teams
This person is not in any offices